Get the Stockscreener App
16.68
0.36%
0.06
After Hours:
17.75
1.07
+6.41%
Bioage Labs Inc stock is traded at $16.68, with a volume of 233.57K.
It is up +0.36% in the last 24 hours and down -4.69% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
See More
Previous Close:
$16.62
Open:
$16.81
24h Volume:
233.57K
Relative Volume:
0.45
Market Cap:
$740.56M
Revenue:
$9.00M
Net Income/Loss:
$-80.61M
P/E Ratio:
-7.4358
EPS:
-2.2432
Net Cash Flow:
$-82.35M
1W Performance:
-4.36%
1M Performance:
-4.69%
6M Performance:
+122.40%
1Y Performance:
+301.93%
1-Day Range:
$16.18
$17.00
1-Week Range:
$16.05
$17.31
52-Week Range:
$3.67
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
16.68 | 737.89M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Needham | Buy |
| Feb-25-26 | Initiated | Oppenheimer | Outperform |
| Feb-18-26 | Upgrade | Jefferies | Hold → Buy |
| Jan-27-26 | Initiated | Piper Sandler | Overweight |
| Dec-05-25 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-22-25 | Upgrade | Citigroup | Neutral → Buy |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
BioAge to preview early data for heart and retinal disease drug - Stock Titan
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - The Manila Times
BlackRock (NYSE: BIOA) reports 2.24M shares of BioAge; 5.03% stake - Stock Titan
BioAge Labs (NASDAQ:BIOA) Trading 8.6% HigherHere's Why - MarketBeat
BioAge Labs plans up to $75M public stock offering; shares down - MSN
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell - MarketBeat
BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares - Stock Titan
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile - MarketBeat
BIOA FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class ActionBIOA - TMX Newsfile
BIOA SEC FilingsBioAge Labs Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1%Time to Sell? - MarketBeat
BIOA (BioAge Labs Inc.) Q4 2025 loss narrows more than expected, shares climb 8.83 percent on investor enthusiasm.Management Guidance - Xã Vĩnh Công
[ARS] BioAge Labs, Inc. SEC Filing - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data By Investing.com - Investing.com South Africa
Directors and auditor up for approval at BioAge Labs (NASDAQ: BIOA) 2026 meeting - Stock Titan
Jefferies reiterates BioAge Labs stock rating on dose data - Investing.com
BioAge Labs (BIOA): Phase 1 BGE-102 Data Reinforce Best-in-Class NLRP3 Potential and De-Risk 2026 Cardiovascular Phase 2, Supporting Buy Rating - TipRanks
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug - BioPharma Dive
BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans - Benzinga
BioAge Reports Positive Phase 1 Data for BGE-102 - Lifespan Research Institute
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - Yahoo Finance
BioAge's BGE-102 Shows Deep Reductions In Inflammation Markers In Phase 1 Trial, Stock Up - RTTNews
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 - Investing.com
BioAge reports Phase 1 results for NLRP3 inhibitor BGE-102 By Investing.com - Investing.com Canada
BGE-102 60 mg once daily achieves equivalent hsCRP reduction as 120 mg, BioAge Labs, Inc. finds - Traders Union
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel - GlobeNewswire
BioAge Labs (BIOA) Stock: Should You Take Exposure (Volatility Increases) 2026-04-20Earnings Beat Stocks - Xã Thanh Hà
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in BioAge Labs, Inc. LawsuitBIOA - ACCESS Newswire
BioAge Labs (NASDAQ:BIOA) Shares Up 10.3%Still a Buy? - MarketBeat
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
BioAge Labs Highlights BGE-102 Catalysts, DME Study Plans and $285M Cash at Needham Conference - MarketBeat
BioAge LabsOral NLRP3 Inhibitor Could Establish PoC In CV This Year (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - The Manila Times
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
Weekly Trades: Is BioAge Labs Inc in accumulation or distribution phaseMarket Activity Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN
Fund Flows: Can BioAge Labs Inc expand its profit margins2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Down 6%Here's What Happened - MarketBeat
The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself — And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells - Baystreet.ca
BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore
Will BioAge Labs (BIOA) Stock Beat Expectations | Price at $17.44, Down 0.34%Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK
BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com South Africa
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan
BIOA Stock Analysis: BioAge Labs Inc. Biotech 1.3% Daily Dip Review at $17.5 - Cổng thông tin điện tử tỉnh Tây Ninh
Bioage Labs Inc Stock (BIOA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):